FDAnews
www.fdanews.com/articles/90472-emea-to-review-thalidomide-pharmion-marketing-authorization-application

EMEA TO REVIEW THALIDOMIDE PHARMION MARKETING AUTHORIZATION APPLICATION

March 2, 2007

Pharmion announced that the European Medicines Agency (EMEA) has accepted for review the company's marketing authorization application for Thalidomide Pharmion (thalidomide) for untreated multiple myeloma. The application is based on a clinical data package comprising four studies in more than 1,400 patients, including a study that showed a 21-month survival advantage when thalidomide was added to the standard of care.

Pharmion is seeking authorization for the following indications: Thalidomide Pharmion in combination with melphalan and prednisone for the treatment of patients with untreated multiple myeloma aged 65 years or older or ineligible for high-dose chemotherapy; and Thalidomide Pharmion in combination with dexamethasone for induction therapy prior to high-dose chemotherapy and bone marrow transplant for the treatment of patients with untreated multiple myeloma. Thalidomide Pharmion must be prescribed and dispensed through the Pharmion Risk Management Programme.

Thalidomide Pharmion has been designated as an orphan medicinal product in the European Union for the treatment of multiple myeloma, which, if approved, entitles the drug to 10 years of market exclusivity for the approved indications.